Research Article | Volume 9, Supplement 1, September, 2021

Biochemical evaluation and molecular docking studies on encapsulated astaxanthin for the growth inhibition of Mycobacterium tuberculosis

Suganya Vasudevan Anuradha Venkatraman Syed Ali Mohammed Yahoob Sasirekha Malathi Jojula Ravikumar Sundaram P Boomi   

Open Access   

Published:  Sep 20, 2021

DOI: 10.7324/JABB.2021.95.1s6

Astaxanthin, a tetraterpenoid compound was formulated as liposomes and screened for anti-tubercular activity against different strains of Mycobacterium tuberculosis: MTB, MDR-TB, and H37Rv isolated from the patient sputum samples. Minimum inhibitory concentration (MIC) was determined by proportion-based method. The molecular docking analysis of astaxanthin with various mycobacterial drug target proteins were performed using in silico tools. Encapsulated astaxanthin showed better inhibition of MTB with MIC value of 500 μg/ml against all the selected strains. The docking analysis provided the interacting amino acid residues of selected mycobacterial enzymes and mode of ligand–protein interaction. Based on the present study, it was concluded that encapsulated astaxanthin could be a better cost-effective natural compound for the treatment of tuberculosis among the patients which will combat side effects in comparison with the first line AntiTB drugs like rifampicin and isoniazid.

Keyword:     Mycobacterium tuberculosis antitubercular activity molecular docking liposomal encapsulation astaxanthin


Vasudevan S, Venkatraman A, Yahoob SAM, Sasirekha, Jojula M, Sundaram R, Boomi P. Biochemical evaluation and molecular docking studies on encapsulated astaxanthin for the growth inhibition of Mycobacterium tuberculosis. J Appl Biol Biotech, 2021;9(S1):31–39.

Copyright: Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike license.

HTML Full Text

1.Moravkova M, Slany M, Trcka I, Havelkova M, Svobodova J, Skoric M. Human-to-human and human-to-dog Mycobacterium tuberculosis transmission studied by IS6110 RFLP analysis: a case report. Vet Med 2011;56:314-7.

2. Centers for Disease Control and Prevention (CDC). Trends in tuberculosis-United States. MMWR Morb Mortal Wkly Rep 2005;18:245-9.

3. Cubillos-Ruiz A, Sandoval A, Ritacco V, López B, Robledo J, Correa N. Genomic signatures of the haarlem lineage of Mycobacterium tuberculosis: implications of strain genetic variation in drug and vaccine development. J Clin Microbiol 2010;48:3614-23.

4. Alix E, Godreuil S, Blanc-Potard AB. Identification of a Haarlem genotype-specific single nucleotide polymorphism in the mgt C virulence gene of Mycobacterium tuberculosis. J Clin Microbiol 2006;44:2093-8.

5. WHO Global Tuberculosis Programme ., WHO, Geneva, Switzerland, 2010. Available via factsheets/fs104/en/index.html.

6. Chidambaram S, Swaminathan R. In-vitro antimycobacterial activity of selected Indian medicinal plants to resistant strains of Mycobacterium tuberculosis. Int J Pharm Sci Res 2016;7:4130-3.

7. Beena D, Rawat S. Antituberculosis drug research: a critical overview. Med Res Rev 2013;33:693-764.

8. O'Niel MJ, Smith A, Heckelman PE. The Merck Index.13th edition, Merck & Co. Inc., New Jersey, p 1785, 2001.

9. Reddy VM, Reddy KR. Synthesis and antimicrobial activity of some novel 4-(1H-benzd]imidazol-2yl)-1,3-thiazol-2-amines. Chem Pharm Bull 2001;58:953-6.

10. Higuera-Ciapara I, Felix-Valenzuela L, Goycoolea FM. Astaxanthin: a review of its chemistry and application. Crit Rev Food Sci Nutr 2006;46:185-96.

11. Yuan JP, Chen F, Li X, Li Z. Carotenoid composition in the green microalga chlorococcum. Food Chem 2002;76:319-25.

12. Dhankhar J, Kadian SS, Sharma A. Astaxanthin: A Potential Carotenoid. Int J Pharm Sci Res 2012;3:1246-359.

13. Suntress EZ. Liposomal antioxidants for protection against oxidantInduced damage. J Toxicol 2011;2011:1-6.

14. Suganya V, Anuradha V, Syed Ali M, Sangeetha P, Bhuvana P. In vitro antioxidant activity of microencapsulated and non-encapsulated astaxanthin. Asian J Sci Technol 2017;8:6391-404.

15. Murahari D, Tanniru S, Poonem L, Paramesh A, Sudheer Kumar K, Jojula M, et al. Anti- mycobacterial screening methods for new compounds identification. Euro J Biomed Pharma Sci 2018;5:584-9.

16. Narender M, Jaswanth SB, Umasankar K, Malathi J, Reddy AR, Umadevi KR, et al. Synthesis, in vitro antimycobacterial evaluation and docking studies of some new 5,6,7,8-tetrahydropyrido [4',3':4,5] thieno [2,3-d] pyrimidin-4(3H)-one schiff bases. Bioorg Med Chem Lett 2016;26:836-40.

17. Bikadi Z, Hazai E. Application of the PM6 semi-empirical method to modelling proteins enhances docking accuracy of Autodock. J Cheminform 2009;1:1-5.

18. Morris GM, Goodsell DS. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998;19:1639-62.<1639::AID-JCC10>3.0.CO;2-B

19. Solis FJ, Wets RJB. Minimization by random search techniques. Math Operations Res 1981;6:19-30.

20. Vivek K, Fatima A, Faridi U, Arvind S, Shanker K, Kumar JK, et al. Antimicrobial potential of Glycyrrhizaglabraroots. J Ethanopharmacol 2008;116:377-80.

21. Ganihiama DU, Sureram S, Sangher S, Honqmanee P, Aree T, Mahidol C, et al. Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis. Eur J Med Chem 2015;89:1-2.

22. Gemechu A, Giday M, Worku A, Ameni G. In vitro Anti-mycobacterial activity of selected medicinal plants against Mycobacterium tuberculosis and Mycobacterium bovis Strains. BMC Complement Altern Med 2013;13:1-6.

23. Calvori C, Frontali L, Leoni L, Tecce G. Effect of rifampicin on protein synthesis. Nature 1965;207:417-8.

24. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 2001;104:901-12.

25. Feklistov A, Mekler V, Jiang Q, Westblade LF, Irschik H, Jansen R, et al. Rifamycins do not function by allosteric modulation of binding of Mg2 + to the RNA. PNAS 2008;105:14820-5.

26. Zhenhua Z. Total variation based denoising model for bioinformatics images. Int J BioaAutomation 2016;20:457-70.

27. Timmins GS, Master S, Rusnak F, Deretic V. Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis. Antimicrob Agents Chem 2004;48:3006-9.

28. Ahmad Z, Klinkenberg LG, Pinn ML, Fraig MM, Peloquin CA, Bishai WR, et al. Biphasic Kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J Infect Dis 2009;200:1136-43.

29. Judd FK, Mijch AM, Cockram A, Norman TR. Isoniazid and antidepressants: is there cause for concern. Int Clin Psychopharmacol 1994;9:123-5.

Article Metrics
26 Views 80 Downloads 106 Total



Related Search

By author names

Similar Articles

Predicted interaction of human Ribosomal Protein S15 with Fragile X Mental Retardation Protein

Edmund Ui-Hang Sim, Xiang-Ru Ma, Stella Li-Li Chan, Choon-Weng Lee, Kumaran Narayanan

Antibacterial potential of Caesalpinia bonducella extracts and their isolated phytoconstituents: in vitro and in silico analysis

S R Santosh Kumar, Sudhesh L Shastri, Venkatesh R, K Pradeepa, V Krishna

Molecular docking and its application in search of antisickling agent from Carica papaya

Dibya Ranjan Das, Dhanesh Kumar, Pravind Kumar, Bisnu Prasad Dash

In silico perceptions in structural elucidation of Exo-ß-1,4-glucanase and Endo-ß-1,3-glucanase from Streptomyces spp.

Lekshmi K. Edison, S. R. Reji, N. S. Pradeep

Virtual screening for novel inhibitors of human Histone Deacetylase 6: Promising new leads for Oral Squamous Cell Carcinoma

Sandhya Vijayasarathy, Jhinuk Chatterjee

Ab-initio modelling and docking evaluation of geographically derived coat proteins of chilli leaf curl virus with flavonoids and chemical compounds

Gnanaprakash Jeyaraj, Habeeb Shaik Mohideen, A. Swapna Geetanjali

Atherosclerotic plaque regression and HMG-CoA reductase inhibition potential of curcumin: An integrative omics and in-vivo study

Priyanka Riyad, Ashok Purohit, Karishma Sen, Heera Ram

Identification of phytocompounds from Paris polyphylla Smith as potential inhibitors against two breast cancer receptors (ERÞ and EGFR tyrosine kinase) through chromatographic and In silico approaches

Debmalya Das Gupta, Saurov Mahanta, Sasti Gopal Das, Sanjib Kumar Das, Dipayan Paul, Hui Tag, Pallabi Kalita Hui

Multitargeted molecular docking study of phytochemicals on hepatocellular carcinoma

Vikas Jha, Anjali Bhosale, Prakruti Kapadia, Agraj Bhargava, Arpita Marick, Zahra Charania, Omkar Parulekar, Mafiz Shaikh, Bhakti Madaye

Evaluating the anti-inflammatory potential of Mesua ferrea linn. stem bark through network pharmacology approach

Jyothsna Kalyana Sundaram, Manjunatha Hanumanthappa, Shivananada Kandagalla, Sharath Belenahalli Shekarappa, Pavan Gollapalli, Umme Hani

In silico screening and analysis of candidate microRNA-target interaction involved in progression of prediabetes to Type II Diabetes Mellitus

Angel Mendonca, Prabu Thandapani, Priya Swaminathan, Sujatha Sundaresan

Phytochemical composition and antiproliferative activity of Opuntia elatior Mill.: In vitro and in silico studies on breast cancer cell line MCF-7

Foram Patel, Khushali Upadhyay, Denni Mammen, Elizabeth Robin, A.V. Ramachandran, Darshee Baxi

Phytochemicals of Nardostachys jatamansi as potential inhibitors of HCV E2 receptor: An in silico study

Lalrintluanga Hnamte, Praveen Nagella, Aatika Nizam, Vasantha Veerappa Lakshmaiah

In silico analysis of garlic phytochemicals binding affinities to skeletal muscle atrophy linked factors through molecular docking

Monika Monika, Sanjeev Gupta, Anita Dua, Ashwani Mittal

Molecular docking analysis of Carica papaya leaf’s bioactive components as prolactin production modulator

Yanti Herawati,, Umi Kalsum, I. Wayan Arsana, Edy Mustofa, Bambang Rahardjo, Karyono Mintaroem, Lelly Yuniarti, Lilis Hadiyati, Teguh W. Sardjono